Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer: A lifetime cost-utility analysis based on a modified Q-TWIST method [3]

European Journal of Clinical Pharmacology

Volumn 53, Issue 3-4, 1997, Pages 281-282

  Trippoli, S ^a   Becagli, P ^a   Messori, A ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

BREAST CANCER; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HUMAN; LETTER; PRIORITY JOURNAL; QUALITY OF LIFE; TECHNIQUE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE;

EID: 0031459657     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050378     Document Type: Letter

References (13)

1. Gelber RD, Goldhirsch A, Cavalli F (1991) Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Int Med 114: 621-628
2. Gelber RD, Lenderking WR, Cotton DJ, Cole BF, Fischl MA, Goldhirsch A, Testa MA (1992) Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. Ann Int Med 116: 961-966
3. Gelber RD, Goldhirsch A, Cole BF, Wieand HS, Schroeder G, Krook JE (1996) A quality-adjusted time without symptoms or toxicity (Q-TWIST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 88: 1039-1045
4. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F, Gray R, Gray R, Gordon NH, Bengtsson NO, Sevelda P (1996) Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone in post-menopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 347: 1066-1071
5. Messori A (1996) Survival curve fitting using the Gompertz function: a methodology for conducting cost-effectiveness analyses on mortality data. Comput Methods Programs Biomed 52: 157-164
6. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML. Nelson CL (1995) Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 332: 1418-1424
7. Messori A, Becagli P, Trippoli S, Tendi E (1996) Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate - fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol 51: 111-116 [erratum (1997) 51: 427]
8. Messori A, Bonistalli L, Costantini M, Trallori G, Tendi E (1996) Cost-effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer. J Clin Gastronterol 23: 269-274
9. Messori A, Becagli P, Trippoli S, Tendi E (1997) A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer 33: 1373-1379
10. Messori A, Trippoli S, Becagli P, Tendi E (1996) Pharmacoeconomic profile of paclitaxel as first-line treatment for patients with advanced ovarian cancer: a lifetime cost-effectiveness analysis. Cancer 78: 2366-2373
11. Messori A, Bonistalli L, Costantini M, Alterini R (1997) Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 19: 275-281
12. Messori A, Cecchi M, Becagli P, Trippoli S (1997) Pharmacoeconomic profile of paclitaxel as first-line treatment for patients with advanced ovarian cancer: a lifetime cost-effectiveness analysis. Cancer [Letter] 79: 2264-2265
13. Bonadonna G, Valagussa P, Moliterni A (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer - the results of 20 years of follow-up. N Engl J Med 332: 901-906